BOSI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.844
EU - Europa 20.814
AS - Asia 11.455
SA - Sud America 1.467
Continente sconosciuto - Info sul continente non disponibili 428
AF - Africa 323
OC - Oceania 264
Totale 67.595
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.373
RU - Federazione Russa 5.799
IT - Italia 4.395
PL - Polonia 4.144
SG - Singapore 3.328
CN - Cina 2.285
HK - Hong Kong 2.061
IE - Irlanda 1.492
SE - Svezia 1.486
VN - Vietnam 1.363
BR - Brasile 1.172
KR - Corea 981
DE - Germania 765
UA - Ucraina 651
FI - Finlandia 607
FR - Francia 546
GB - Regno Unito 427
IN - India 422
CA - Canada 311
AU - Australia 256
CH - Svizzera 201
TR - Turchia 175
JP - Giappone 140
JO - Giordania 122
AR - Argentina 116
BD - Bangladesh 116
IQ - Iraq 103
ID - Indonesia 96
ES - Italia 78
NL - Olanda 68
CI - Costa d'Avorio 61
MX - Messico 57
ZA - Sudafrica 56
NG - Nigeria 45
EC - Ecuador 41
VE - Venezuela 33
MA - Marocco 32
CO - Colombia 30
CL - Cile 29
AT - Austria 27
BE - Belgio 27
PK - Pakistan 25
AE - Emirati Arabi Uniti 24
KE - Kenya 22
SC - Seychelles 22
PH - Filippine 20
UZ - Uzbekistan 20
SA - Arabia Saudita 19
CR - Costa Rica 18
TN - Tunisia 18
DZ - Algeria 17
JM - Giamaica 17
PY - Paraguay 17
EG - Egitto 16
TH - Thailandia 16
MY - Malesia 15
NP - Nepal 13
AZ - Azerbaigian 12
PE - Perù 12
TT - Trinidad e Tobago 12
AL - Albania 11
KZ - Kazakistan 11
TW - Taiwan 11
SV - El Salvador 10
BO - Bolivia 9
ET - Etiopia 9
GT - Guatemala 9
HN - Honduras 9
IL - Israele 9
IR - Iran 9
LT - Lituania 9
MU - Mauritius 8
UY - Uruguay 8
HR - Croazia 7
OM - Oman 7
BY - Bielorussia 6
LB - Libano 6
NZ - Nuova Zelanda 6
PA - Panama 6
RO - Romania 6
RS - Serbia 6
BH - Bahrain 5
DO - Repubblica Dominicana 5
EE - Estonia 5
EU - Europa 5
GR - Grecia 5
KG - Kirghizistan 5
MN - Mongolia 5
SN - Senegal 5
SY - Repubblica araba siriana 5
BS - Bahamas 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
GE - Georgia 4
HU - Ungheria 4
LU - Lussemburgo 4
NO - Norvegia 4
PR - Porto Rico 4
PS - Palestinian Territory 4
PT - Portogallo 4
Totale 67.109
Salva come PNG Salva come JPEG
Città #
Santa Clara 5.097
Warsaw 4.126
Fairfield 3.502
Ashburn 3.214
Singapore 2.293
Chandler 1.836
Hong Kong 1.675
Woodbridge 1.596
Dublin 1.486
Seattle 1.442
Cambridge 1.337
Houston 1.196
Wilmington 1.161
Jacksonville 1.028
Seoul 966
Milan 893
San Jose 643
Beijing 575
Ann Arbor 556
Princeton 547
Council Bluffs 490
Altamura 487
Lawrence 482
Buffalo 442
The Dalles 406
Ho Chi Minh City 400
Los Angeles 384
Rome 364
Lauterbourg 361
Hanoi 327
Boston 300
Boardman 289
Mumbai 272
Hefei 252
Melbourne 247
Medford 238
Dallas 215
Moscow 209
Florence 203
New York 189
Bern 187
San Diego 177
Munich 153
Clifton 148
Helsinki 148
Shanghai 117
Izmir 112
Turin 109
Naples 99
Tokyo 99
Kent 96
São Paulo 90
Redondo Beach 87
Toronto 85
Bologna 84
Falls Church 84
Norwalk 75
Montreal 69
Columbus 66
Salerno 66
Frankfurt am Main 65
Dong Ket 64
Chicago 63
Paris 62
Abidjan 61
Palermo 61
Turku 60
Verona 60
London 57
Bremen 56
Figino 56
Jakarta 54
Phoenix 54
Da Nang 53
Haiphong 51
Hillsboro 48
Guangzhou 46
Orem 46
Tianjin 45
Abuja 41
Brescia 41
Genoa 41
Rio de Janeiro 38
Baghdad 37
Miano 35
Venice 35
Yubileyny 35
Brooklyn 34
Andover 33
Atlanta 33
Barcelona 33
Padua 33
Bari 32
Chennai 31
Manchester 31
Belo Horizonte 29
Denver 29
Hải Dương 29
San Francisco 28
Johannesburg 27
Totale 45.644
Salva come PNG Salva come JPEG
Nome #
Lesioni cutanee «specifiche» in corso di leucemia linfatica cronica. 632
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 450
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 393
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 390
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 349
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 347
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 347
Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals 342
Patients with ≥ 20 × 10(9)/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience. 341
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 336
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 334
Dendritic cells with lymphocyte stimulating activity differentiate from human CD133 positive precursors. 332
[The treatment of diffuse cutaneous systemic sclerosis with autologous hemopoietic stem cells transplantation (HSCT): our experience on 2 cases]. 331
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. 329
EZH2 mutational status predicts poor survival in myelofibrosis. 328
Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model 328
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 326
CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease. 326
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 323
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 321
Hepcidin levels and their determinants in different types of myelodysplastic syndromes 313
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 309
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 308
Primary cutaneous follicular centre- cell lymphoma- a lymphoproliferative disease with favourable prognosis. 308
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 307
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. 300
Dendritic cells in the skin after allogeneic bone marrow transplantation: immunohistochemical and electron microscopic monitoring 294
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 287
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. 281
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 276
Familial Hemophagocytic Lymphohistiocytosis May Present during Adulthood: Clinical and Genetic Features of a Small Series 274
The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas 269
Increase in FOXP3(+) Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response 260
Localized scleroderma-like lesions in autologous bone marrow transplantation. 255
Trapianto intracerebrale di striato fetale nella malattia di Huntington: un aggiornamento dell'esperienza clinica italiana 252
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. 249
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. 239
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. 234
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 230
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 228
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 226
AFLP epidemiological investigation of an outbreak of Pseudomonas aeruginosa sepsis in stem cell transplantation patients 225
18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. 224
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial 222
Differences among young adults, adults and elderly chronic myeloid leukemia patients 221
Neutral Maltase Activity in Leucocytic PopulationNew Trends in Experimental Hematology, Serono Simposia 220
Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia 220
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 218
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 218
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 218
Molecular characterization of Acinetobacter isolates collected in intensive care units of six hospitals in Florence, Italy, during a 3-year surveillance program: a population structure analysis 217
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience. 217
Inorganic nanoparticles as potential regulators of immune response in dendritic cells 216
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 214
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 212
ATP modulates cell proliferation and elicits two different electrophysiological responses in human mesenchymal stem cells. 209
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 208
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML 208
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. 206
New patterns of relapse in multiple myeloma: A case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation 206
Attività della maltasi neutra sulla membrana dei granulociti.31° Congresso Nazionale S.I.B. Rimini, 15-18 Settembre 1985. Abs. B21 205
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR 205
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 205
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 204
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 202
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 202
Time related variations in stem cell harvesting of umbilical cord blood 202
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study 202
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 201
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo 200
Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. 200
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey 200
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 200
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 200
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 199
A life-threatening ruxolitinib discontinuation syndrome 199
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 198
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 198
Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report 197
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide 197
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. 195
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. 195
ACUTE HEPATITIS C VIRUS INFECTION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES 194
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial 194
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 193
Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. 193
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 192
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 192
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 191
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 191
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML 191
Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. 190
A prospective, open-label noncomparative study with piperacillin-tazobactam monotherapy as management of Fever in patients with acute leukemia. 190
Chemotherapy-related nail toxicity 189
A reappraisal of the histopathologic criteria for the diagnosis of cutaneous allogeneic acute graft-vs-host disease 188
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach 188
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. 188
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 188
Treatment options for essential thrombocythemia and polycythemia vera 187
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 187
Totale 24.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.896 0 308 223 128 130 143 130 214 168 116 480 856
2022/20237.517 834 1.307 307 608 665 1.357 792 430 689 48 221 259
2023/20242.286 144 302 463 99 142 291 94 380 27 104 127 113
2024/202515.805 620 1.843 1.052 2.340 4.391 1.890 203 1.136 966 427 516 421
2025/202617.706 1.738 2.306 1.219 1.117 1.924 778 2.131 1.028 1.117 955 447 2.946
2026/20271.315 561 754 0 0 0 0 0 0 0 0 0 0
Totale 67.595